A Gastroenterologist's Guide to Probiotics

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 9, 2012, Pages 960-968

  Ciorba, Matthew A ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Clostridium difficile; Crohn's Disease and Colitis; IBD; IBS; Pouchitis; Yogurt

Indexed keywords

MESALAZINE; PROBIOTIC AGENT; TRANSCRIPTOME; YOGHURT;

ALGORITHM; BIFIDOBACTERIUM; BIOREACTOR; BLOATING; CLOSTRIDIUM DIFFICILE INFECTION; COLONY FORMING UNIT; DISEASE COURSE; DISEASE SEVERITY; ENTERITIS; GASTROENTEROLOGY; HEALTH; HEPATIC ENCEPHALOPATHY; HUMAN; ILEITIS; INCIDENCE; IRRITABLE COLON; LACTOBACILLUS; MEDICAL PRACTICE; MICROBIOME; NONHUMAN; REMISSION; REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; ULCERATIVE COLITIS;

BACTERIA; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL DISEASES; HUMANS; METAGENOME; PROBIOTICS;

EID: 84865314484     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.03.024     Document Type: Review

References (85)

1. Williams M.D., Ha C.Y., Ciorba M.A. Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations. J Clin Gastroenterol 2010, 44:631-636.
2. Kau A.L., Ahern P.P., Griffin N.W., et al. Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
3. Macpherson A.J., Harris N.L. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 2004, 4:478-485.
4. Sekirov I., Russell S.L., Antunes L.C., et al. Gut microbiota in health and disease. Physiol Rev 2010, 90:859-904.
5. Ng S.C., Hart A.L., Kamm M.A., et al. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009, 15:300-310.
6. Madsen K.L. Interactions between microbes and the gut epithelium. J Clin Gastroenterol 2011, 45(Suppl):S111-S114.
7. Rousseaux C., Thuru X., Gelot A., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007, 13:35-37.
8. Ciorba M.A., Riehl T.E., Rao M.S., et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut 2012, 61:829-838.
9. Yan F., Cao H., Cover T.L., et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest 2011, 121:2242-2253.
10. Shanahan F. Probiotics in perspective. Gastroenterology 2010, 139:1808-1812.
11. Mileti E., Matteoli G., Iliev I.D., et al. Comparison of the immunomodulatory properties of three probiotic strains of lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 2009, 4:e7056.
12. Berman S., Spicer D. Safety and reliability of lactobacillus supplements in Seattle, Washington. Internet J Altern Med 2003, 1(2).
13. Sanders M.E. Impact of probiotics on colonizing microbiota of the gut. J Clin Gastroenterol 2011, 45(Suppl):S115-S119.
14. McNulty N.P., Yatsunenko T., Hsiao A., et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med 2011, 3. 106ra106.
15. Thomas D.W., Greer F.R., et al. Probiotics and prebiotics in pediatrics. Pediatrics 2010, 126:1217-1231. American Academy of Pediatrics Committee on Nutrition.
16. Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 2011, 45(Suppl):S149-S153.
17. Weizman Z., Asli G., Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005, 115:5-9.
18. Pedone C.A., Arnaud C.C., Postaire E.R., et al. Multicentric study of the effect of milk fermented by Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract 2000, 54:568-571.
19. Szajewska H., Kotowska M., Mrukowicz J.Z., et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001, 138:361-365.
20. Szymański H., Pejcz J., Jawień M., et al. Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains-a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006, 23:247-253.
21. Allen S.J., Martinez E.G., Gregorio G.V., et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010, CD003048.
22. Johnston B.C., Goldenberg J.Z., Vandvik P.O., et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011, CD004827.
23. Szajewska H., Ruszczyński M., Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006, 149:367-372.
24. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101:812-822.
25. Hickson M., D'Souza A.L., Muthu N., et al. Use of probiotic lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007, 335:80.
26. Gao X.W., Mubasher M., Fang C.Y., et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010, 105:1636-1641.
27. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 2008, 359:1932-1940.
28. Lo Vecchio A., Zacur G.M. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012, 28:1-9.
29. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994, 271:1913-1918.
30. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000, 31:1012-1017.
31. Na X., Kelly C. Probiotics in Clostridium difficile infection. J Clin Gastroenterol 2011, 45(Suppl):S154-S158.
32. Floch M.H., Walker W.A., Madsen K., et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol 2011, 45(Suppl):S168-S171.
33. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
34. Brandt L.J., Chey W.D., et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009, 104(Suppl 1):S1-S35. American College of Gastroenterology Task Force on Irritable Bowel Syndrome.
35. Carroll I.M., Ringel-Kulka T., Keku T.O., et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011, 301:G799-G807.
36. Kassinen A., Krogius-Kurikka L., Mäkivuokko H., et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007, 133:24-33.
37. Marshall J.K., Thabane M., Garg A.X., et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006, 131:445-450.
38. Spiller R., Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009, 136:1979-1988.
39. Ford A.C., Spiegel B.M., Talley N.J., et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009, 7:1279-1286.
40. Pimentel M., Lembo A., Chey W.D., et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011, 364:22-32.
41. Spiegel B.M. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol 2011, 9:461-469.
42. Ringel Y., Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol 2011, 45(Suppl):S145-S148.
43. Moayyedi P., Ford A.C., Talley N.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010, 59:325-332.
44. Brenner D.M., Moeller M.J., Chey W.D., et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009, 104:1033-1049.
45. Horvath A., Dziechciarz P., Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 2011, 33:1302-1310.
46. O'Mahony L., McCarthy J., Kelly P., et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
47. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006, 101:1581-1590.
48. Guarner F., Khan A.G., Garisch J., et al. World Gastroenterology Organisation Practice Guideline-Probiotics and Prebiotics Accessed January 1, 2012. http://www.worldgastroenterology.org/probiotics-prebiotics.html.
49. Abraham C., Cho J.H. Inflammatory bowel disease. N Engl J Med 2009, 361:2066-2078.
50. Sartor R.B. Genetics and environmental interactions shape the intestinal microbiome to promote inflammatory bowel disease versus mucosal homeostasis. Gastroenterology 2010, 139:1816-1819.
51. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
52. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620-1633.
53. Danese S., Fiocchi C. Ulcerative colitis. N Engl J Med 2011, 365:1713-1725.
54. Schultz M., Timmer A., Herfarth H.H., et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004, 4:5.
55. Bousvaros A., Guandalini S., Baldassano R.N., et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005, 11:833-839.
56. Prantera C., Scribano M.L., Falasco G., et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002, 51:405-409.
57. Meijer B.J., Dieleman L.A. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol 2011, 45(Suppl):S139-S144.
58. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623.
59. Tursi A., Brandimarte G., Papa A., et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010, 105:2218-2227.
60. Sood A., Midha V., Makharia G.K., et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009, 7:1202-1209. 1209.e1201.
61. Miele E., Pascarella F., Giannetti E., et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009, 104:437-443.
62. Naidoo K., Gordon M., Fagbemi A.O., et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011, CD007443.
63. Fujimori S., Gudis K., Mitsui K., et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 2009, 25:520-525.
64. Shanahan F., Guaraner F., von Wright A., et al. A one year, double-blind, placebo controlled trial of a Lactobacillus or a Bidfidobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology 2006, 130:A-44. 249.
65. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
66. Mimura T., Rizzello F., Helwig U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
67. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
68. Shen B., Brzezinski A., Fazio V.W., et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005, 22:721-728.
69. Gosselink M.P., Schouten W.R., van Lieshout L.M., et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004, 47:876-884.
70. Pardi D.S., D'Haens G., Shen B., et al. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis 2009, 15:1424-1431.
71. Holubar S.D., Cima R.R., Sandborn W.J., et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010, CD001176.
72. Lata J., Jurankova J., Kopacova M., et al. Probiotics in hepatology. World J Gastroenterol 2011, 17:2890-2896.
73. Macbeth W.A., Kass E.H., McDermott W.V. Treatment of hepatic encephalopathy by alteration of intestinal flora with lactobacillus acidophilus. Lancet 1965, 1:399-403.
74. Liu Q., Duan Z.P., Ha D.K., et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449.
75. Bajaj J.S., Saeian K., Christensen K.M., et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008, 103:1707-1715.
76. Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy, Accessed December 11, 2011. http://clinicaltrials.gov/ct2/show/NCT00992290.
77. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008, 46(Suppl 2):S104-S111. Discussion:S144-S151.
78. Hempel S., Newberry S., Ruelaz A., et al. Safety of Probiotics to Reduce Risk and Prevent or Treat Disease. US Department of Health and Human Services 2011, http://www.ahrq.gov/clinic/tp/probiotictp.htm#Report.
79. Besselink M.G., van Santvoort H.C., Buskens E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659.
80. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 2006, 83:1256-1264. Quiz:1446-1257.
81. Ciorba M.A., Stenson W.F. Probiotic therapy in radiation-induced intestinal injury and repair. Ann N Y Acad Sci 2009, 1165:190-194.
82. Packey C.D., Ciorba M.A. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol 2010, 26:88-94.
83. Shanahan F., Collins S.M. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality. Gastroenterol Clin North Am 2010, 39:721-726.
84. Mowat C., Cole A., Windsor A., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60:571-607.
85. Levels of Evidence Centre for Evidence Based Medicine, Accessed Feb 1, 2012. http://www.cebm.net/index.aspx?o=1025.